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Purpose—The genetic etiology of atrioventricular septal defect (AVSD) is unknown in 40% 
cases. Conventional sequencing and arrays have identified the etiology in only a minority of non-
syndromic individuals with AVSD.
Methods—Whole exome sequencing was performed in 81 unrelated probands with AVSD to 
identify potentially causal variants in a comprehensive set of 112 genes with strong biological 
relevance to AVSD.
Results—A significant enrichment of rare and rare/damaging variants was identified in the gene 
set, compared with controls (odds ratio 1.52, 95% confidence interval 1.35–1.71, p = 4.8 x 10-11). 
The enrichment was specific to AVSD probands compared with a non-AVSD cohort with tetralogy 
of Fallot (odds ratio 2.25, 95% confidence interval 1.84-2.76, p = 2.2 x 10-16). Six genes (NIPBL, 
CHD7, CEP152, BMPR1a, ZFPM2 and MDM4) were enriched for rare variants in AVSD 
compared to controls, including three syndrome-associated genes (NIPBL, CHD7, CEP152). The 
findings were confirmed in a replication cohort of 81 AVSD probands.
Conclusion—Mutations in genes with strong biological relevance to AVSD, including 
syndrome-associated genes, can contribute to AVSD even in those with isolated heart disease. The 
identification of a gene set associated with AVSD will facilitate targeted genetic screening in this 
cohort.
Keywords
whole exome sequencing; targeted sequencing; atrioventricular septal defect; endocardial cushion 
defect; atrioventricular canal defect; congenital heart disease; Cornelia de Lange syndrome; 
CHARGE syndrome
Introduction
Atrioventricular septal defect (AVSD) is a relatively rare disorder, representing 7% of all 
congenital heart defects (CHD).1 Although AVSD is most often associated with trisomy 21 
or heterotaxy, approximately 40% of patients have neither of these associations. Within this 
etiologically diverse group of patients, approximately 30% have an identifiable genetic 
diagnosis relating to a chromosomal or single gene disorder, 10% have non-diagnostic 
dysmorphic features or extracardiac anomalies, and the remainder have no discernible 
extracardiac anomalies (non-syndromic AVSD).1,2 To date, targeted sequencing,3–5 and 
interrogation for large copy number variants6 have identified the etiology in only a minority 
of non-syndromic individuals with AVSD. Traditional gene discovery strategies are limited 
in AVSD due to locus heterogeneity, possible reduced penetrance and relatively small 
numbers of cases and families. We recently reported results of an unsupervised analysis of 
whole exome sequencing (WES) data in AVSD probands that identified rare causal variants 
in NR2F2.7 To identify additional genetic causes in this cohort, we analyzed for potentially 
causal variants in all known genes with biological relevance to AVSD.
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Methods
Study Population
Patients were prospectively enrolled in an Ontario province-wide Heart Centre Biobank 
registry after informed consent. The study was approved by the Research Ethics Boards of 
the Hospital for Sick Children and all other participating sites.8,9 The primary cohort 
included unrelated probands with AVSD of Caucasian race. Principal component analysis 
was performed to confirm overlap with HapMap individuals of Caucasian ancestry (Figure 
S1). Patients with an identified chromosomal or syndromic disorder, or a situs anomaly were 
excluded. Detailed cardiac and extra-cardiac features were assessed through review of 
medical records, imaging, and dysmorphology assessment, when possible.
Data for replication analysis (n = 81) were obtained from WES of 44 AVSD probands (GO-
CHD, Oxford registry; Leuven, Belgium) provided by the Wellcome Trust Sanger Institute 
(WTSI) (previously described)7, and 37 AVSD probands from the CONCOR registry DNA-
bank of the University Cardiology Institute Netherlands (ICIN) and the Ontario Heart Centre 
Biobank Registry who underwent targeted sequencing. All probands in the replication cohort 
were unrelated, non-syndromic and Caucasian. Sixty-four unrelated Caucasian probands 
from the Heart Centre Biobank Registry with isolated Tetralogy of Fallot (TOF) underwent 
WES as a non-AVSD CHD cohort.
Variant calls from WES of 4300 individuals of European American ancestry from the 
NHLBI Exome Sequencing Project Exome Variant Server10 (EVS) served as controls 
(“EVS Controls”). Additional controls included whole genome sequencing data from 40 
unaffected parents of children with autism spectrum disorders (S. Walker, S.W. Scherer, 
personal communication), and targeted genotyping in 97 unaffected Caucasian population-
matched Ontario controls without heart disease.
Whole Exome Sequencing
WES was performed using the Agilent SureSelect Target Enrichment Kit (V3 50Mb) 
(Agilent Technologies Inc., Santa Clara, CA) for sequence capture and Illumina HiSeq2500 
(75 bp paired-end reads) for sequencing (Illumina Inc., San Diego, CA) to a target depth of 
100X, as previously published.7 The non-AVSD cohort was sequenced using the Agilent 
SureSelect Target Enrichment Kit (V4 51 Mb) (Agilent Technologies Inc., Santa Clara, CA) 
for sequence capture and Illumina HiSeq (90bp paired-end reads) for sequencing (Illumina 
Inc. San Diego, CA) (BGI Genomics, Philadelphia, PA) to a target depth of 50X.
AVSD Gene List
A systematic review of the literature was undertaken to curate all genes associated with 
AVSD identified in previous human and animal studies (Table S1). This generated a list of 
112 AVSD genes including 47 associated with human syndromes, 30 with animal models, 
20 with both human and animal references, 9 with isolated AVSD in humans, and 6 reported 
as cardiac modifiers in trisomy 21. Of these 112 genes, 58 were associated with syndromic 
CHD (“syndromic” genes).
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Variant Filtering
Variants in these 112 genes were filtered for quality, leaving only calls with a passing GATK 
score (99% accuracy in read determination)11 and read-depth coverage of ≥ 30. Non-
synonymous, non-synonymous splice, stop-gain and stop-loss variants were prioritized. The 
variants were annotated with Annovar12 to obtain the minor allele frequency (MAF) for 
each variant from 1000Genomes13 and EVS.10 Rare variants, defined as MAF < 0.01 in 
1000G and EVS European American (EA) ancestry, were prioritized, and included novel 
variants i.e. variants not present in either 1000Genomes, EVS datasets or in the Database of 
Single Nucleotide Polymorphisms (dbSNP).14 Variants were annotated with SIFT15 and 
PolyPhen216 and any variant predicted to be pathogenic in at least one program was called 
damaging. Evolutionary conservation was defined as PhyloP score > 0 (range -14 to +6; 
sites predicted to be conserved are assigned positive scores)17 and/or PhastCONS ≥ 0.8 
(range 0-1 where 1 indicates a highly conserved locus).18
Mutation Burden Analysis
The overall burden of rare (including novel) non-synonymous variants and rare synonymous 
variants in the AVSD, EVS and non-AVSD CHD cohorts was assessed across all 112 genes. 
The EVS does not provide sample level information; therefore for consistency the burden 
analysis assumes that each genotype represents an independent sample. Variant data from 
EVS Control and non-AVSD CHD cohorts were filtered in the same manner as the case data. 
To assess mutation burden, Fisher’s exact test was performed across all 112 genes for the 
number of individuals with and without rare and rare/damaging non-synonymous and rare 
synonymous variants in cases and controls. A control burden analysis was also performed 
using a list of 11 autism-spectrum disorder genes19 (refer to Figure S2).
Coverage Analysis
To ensure that a difference in mutation burden across these 112 genes was not secondary to 
differences in coverage of genomic regions between cohorts, coverage analysis was 
performed in cases and controls. Consensus coding sequence exon coordinates for all exons 
in 112 genes were extracted from University of California Santa Cruz Table Browser20 and 
the mean depth per coding base pair was calculated across all BAM files as previously 
described.21 The percentage of bases covered to a depth of ≥ 20 for 112 genes was 
calculated and the distribution was compared between AVSD, EVS and non-AVSD CHD 
cohorts using Student’s T-Test (two-tailed). A nucleotide-by-nucleotide coverage analysis 
was then undertaken to verify adequate case and control coverage at each locus 
corresponding to variant location. Variants were excluded from the mutation burden 
calculation if the average depth of coverage in either cohort was <20.
Variant Validation
All prioritized variants were verified by Sanger’s di-deoxy nucleotide sequencing. The 
amplified products were subjected to di-deoxy nucleotide PCR amplification and were 
sequenced on 3730xl DNA Analyzer (Applied Biosystems, Life Technologies, Grand Island, 
NY) (Table S2.1). The sequence chromatograms were aligned to primer target regions using 
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CodonCode Aligner (CodonCode Corporation, Centerville, MA). Parental genotypes were 
evaluated if parental DNA was available.
Replication
Genes enriched for rare (including novel) and rare/damaging non-synonymous variants in 
AVSD cases vs. EVS controls on mutation burden analysis were selected for targeted 
sequencing in the replication cohort using Agilent Haloplex Custom Target Enrichment 
(Agilent Technologies Inc., Santa Clara, CA). A custom probe set was designed using 
Agilent SureDesign web-based software to target all coding exons for the prioritized genes 
(earray.chem.agilent.com/suredesign). Sequencing (100 bp paired-end reads, targeted at 
>200X coverage) was performed using Illumina HiSeq2500 (Illumina Inc., San Diego, CA) 
at The Centre for Applied Genomics (TCAG) in The Hospital for Sick Children. Agilent 
SureCall software was used to generate BAM files and perform variant calling. Variants 
were annotated and filtered using the same protocol as for the primary cohort. To assess the 
population frequency of the recurring variant in MDM4 [8:204518457 A>C (K324Q, 
rs41299595)], genotyping was performed in 97 Caucasian controls without heart disease 
from Ontario using a custom-designed TaqMan® SNP Assays (Life Technologies 
Corporation) (Table S2.2). Samples were analyzed using the ViiA™ 7 Real-Time PCR 
System with ViiA™7 software.
Results
Of 260 individuals with AVSD enrolled in the Heart Centre Biobank Registry, 83 probands 
were eligible for inclusion and underwent WES (Table 1). Variants in 112 genes from 81 
unrelated probands (2 probands did not sequence) were filtered to identify 163 unique rare 
variants, of which 91 were predicted to be damaging (Figure S3).
The AVSD Cohort was enriched for rare and rare/damaging variants
A mutation burden analysis across all 112 genes was conducted to assess for enrichment of 
rare variants in the AVSD cohort compared with EVS Controls. There was no difference 
between the two cohorts in the frequency of rare synonymous variants (1.6% vs. 1.6%; Odds 
Ratio 1.01, p = 0.9). The frequency of rare non-synonymous variants however, was higher in 
the AVSD cohort (3.2%) compared to the EVS Controls (2.1%) (OR 1.52, p = 4.8 x 10-11), 
as was the frequency of rare/damaging variants in the AVSD (1.5%) versus EVS Controls 
(1.2%) (OR 1.26, p = 0.01) (Figure 1, Table S3.1). We also observed an enrichment of rare 
non-synonymous variants in the AVSD cohort vs. EVS controls when comparing only the 
subset of 58 syndromic genes (OR 1.32, p=0.001) (Table S3.1). There was no enrichment of 
rare or rare damaging non-synonymous variants in the AVSD cohort compared with the EVS 
cohort when the same analysis was conducted with a control set of 11 autism-spectrum 
genes (Figure S2).
To assess whether the enrichment was specific to AVSD or also seen in other forms of CHD, 
mutation burden was compared to a non-AVSD CHD cohort (TOF). Again, there was no 
significant difference between the cohorts in the frequency of rare synonymous variants 
(1.6% vs. 1.4%; OR 1.12, p = 0.3) (Figure 1, Table S3.2). However, the AVSD cohort was 
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enriched for rare non-synonymous variants in the 112 genes (3.2% vs. 1.4%; OR 2.33, p = 
2.2 x 10-14) and rare damaging non-synonymous variants (1.5% vs. 0.7%; OR 2.11, p = 2.1 
x 10-6) compared with the non-AVSD CHD cohort. Enrichment of variants in the AVSD vs. 
non-AVSD CHD cohort was also seen when analysis was limited to only 58 syndromic 
genes (Table S3.2)
To ensure that enrichment of variants in the AVSD cohort was not related to differences in 
coverage between cohorts, we compared coverage across the 112 genes in the AVSD cohort 
versus EVS Control and non-AVSD CHD cohorts. The mean percentage of bases covered to 
a depth of ≥ 20 for all 112 genes was similar between the AVSD (83.0 ± 22%) versus the 
non-AVSD CHD cohort (81.8 ± 14.6%, p = 0.63) but lower than the EVS controls (89.7 
± 18.9%, p = 0.02). Therefore the higher mutation burden in AVSD cases was not due to 
underreporting of variants in controls or in non-AVSD CHD cohort (Figure S4). The 
enrichment for rare and rare/damaging variants in AVSD cases remained significant when 
analysis was corrected for nucleotide-by-nucleotide coverage by excluding variants that did 
not meet the depth cut-offs in both cohorts (Tables S3.1, 3.2).
Genotype-phenotype associations
As reported previously, NR2F2 was significantly enriched for both rare and rare/damaging 
variants.7 Besides NR2F2, six genes showed significant enrichment for rare and novel non-
synonymous variants, with MDM4 remaining significant after correction for multiple testing 
across 112 genes. These genes, NIPBL, CHD7, CEP152, BMPR1a, ZFPM2 and MDM4, 
were prioritized for validation by Sanger sequencing, replication, and determination of 
inheritance patterns (Table 2; Figure S5). Across the 6 prioritized genes, 23 probands had 
rare/novel damaging variants (Tables 3, 4 and S4). Given that many of these genes are 
syndrome-associated, patients were further assessed for extra-cardiac anomalies. Genotype-
phenotype associations for individual genes are described below.
NIPBL—Six AVSD probands (7.4%) had rare non-synonymous variants in NIPBL 
compared with 2.3% in EVS controls (OR 3.3, p=0.02) (Table 2). The M1318V and S2471T 
variants were novel, highly conserved and predicted to be damaging (Tables 3 and S4). The 
N105D and N393K variants were each previously seen in a single individual among 4300 
EVS EA controls, and not in the other control datasets. Both variants are conserved and the 
N105D variant is predicted to be damaging. The A179T variant (AVSD_65) was also 
identified in one individual in the replication cohort (Table S5) and in one non-AVSD CHD 
proband. Although it has been previously reported in 29 individuals in the EA EVS, and in 
1000G and dbSNP, it is listed in the Human Gene Mutation Database as a potentially disease 
causing variant (Table S4). An additional variant I314V was identified in the replication 
cohort (Table S5), which has not been previously reported in public datasets. NIPBL 
mutations are known to be associated with Cornelia de Lange syndrome (CDL). However, 
none of the AVSD probands with NIPBL variants had clinical characteristics of CDL (Table 
4) although 2 probands had associated semilunar valve anomalies (AVSD_33 and 
AVSD_72), which are commonly associated with CDL.
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CHD7—Nine AVSD probands (11.1%) had rare non-synonymous variants in CHD7 
compared with 5.0% of EVS controls (OR = 2.3, p=0.04) (Table 2). The T93A, Y1325H, 
A2105V and S2383C variants were all novel or exceptionally rare (Y1325H seen in 1 EVS 
individual). All were conserved and the A2105V, Y1325H and S2383C variants were 
predicted to be damaging. The M340V and M2527L variants seen in probands and in the 
replication cohort (Table S5) were also seen in the EVS dataset (62 and 43 individuals) and 
were predicted to be benign. Three additional rare non-synonymous variants were identified 
in the replication cohort: A1950T, P2083S and L935F (Table S5). None of the variants were 
seen in 40 unaffected parents from an Ontario-based cohort of families with autism spectrum 
disorders. CHD7 mutations are known to be associated with CHARGE syndrome. However, 
six of nine probands with CHD7 variants had isolated cardiac disease. One proband had 
dysmorphic features and extra-cardiac anomalies but none of the diagnostic features of 
CHARGE syndrome. The other two probands had single minor anomalies, unrelated to 
CHARGE syndrome (Table 4).
CEP152—Rare non-synonymous variants in CEP152 were seen in 9.7% of AVSD cases 
compared with 4.3% in EVS controls (OR = 2.4, p=0.03) (Table 2). The L581I variant was 
novel, while the T1524A, L1105V, W960R, I294V, and S85R variants were all rare. Only 
the W960R variant was highly conserved and predicted to be damaging. Two additional 
variants were identified in the replication cohort, G181D and R115Q (Table S5). None of the 
variants were seen in 40 unaffected parents from an Ontario-based cohort of families with 
autism spectrum disorders. All variants were heterozygous and none of the probands had 
features consistent with Seckel syndrome, dwarfism or microcephaly, known to be 
associated with defects in CEP152 (Table 4).
BMPR1a—Rare non-synonymous variants in BMPR1a were identified with in 3.7% of 
AVSD cases compared with 0.7% in EVS controls (OR = 5.3, p = 0.02) (Table 2). All three 
variants (R478H, D429V and P481S) were exceptionally rare and predicted to be damaging 
(Table 4). Two probands (AVSD_2 and AVSD_17) had isolated cardiac disease, and 
AVSD_57 also had learning and psychiatric disabilities and cervical spine anomalies. 
AVSD_17 and AVSD_57 both had a left superior vena cava to coronary sinus (Table 4).
ZFPM2—Rare non-synonymous variants in ZFPM2 were seen in 13.6% of AVSD cases 
compared with 6.7% of EVS controls (p = 0.03, OR = 2.2). Two variants (P361S and 
G885S) were exceptionally rare in EVS and absent in the other control datasets. Both these 
variants were conserved and the P361S variant was predicted to be damaging. Six of the 9 
AVSD probands with ZFPM2 variants had a second variant in one of the 6 priority genes, 
including 2 probands with 2 heterozygous ZFPM2 variants. Of these, AVSD_53 had 
associated anomalies including pulmonary atresia with major aortopulmonary collaterals, 
and multiple extracardiac anomalies including a diaphragmatic hernia (P361S and E30G). 
The E30G, D98N, M544I and V631I variants in the AVSD cohort and the S210T variant in 
the non-AVSD TOF cohort were also identified in the replication cohort, along with 
D1051Y, a novel variant. Additionally, 5 individuals in the non-AVSD CHD cohort had 
ZFPM2 variants, none of which recurred in the AVSD cohort.
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MDM4—Rare non-synonymous variants in MDM4 were seen in 7.4% of AVSD cases 
compared with 1.2% of EVS controls (OR = 5.0, p = 3.2 x 10-4). One variant, K324Q was 
seen in 5 (unrelated) probands (MAF = 0.061), and also in 1 unaffected autism control (S. 
Walker and S.W. Scherer personal communication) and 40 EVS individuals (MAF = 
0.0047). As this single variant was seen with a high frequency in our cohort, genotyping was 
undertaken in 97 unaffected controls. The K324Q variant was seen at a lower frequency in 
controls (2/97 or 2.1%) compared to AVSD cases (6.1%) (p = 0.003). The P338A variant 
identified in AVSD_29 was seen in 4 EVS individuals, but not in 1000G or in unaffected 
autism controls. An additional three variants were identified in the replication cohort (Table 
S5). All the probands with MDM4 variants had isolated cardiac disease.
Compound mutations
Of the 34 probands with variants in the 6 prioritized genes, 8 probands had more than one 
rare or rare/damaging non-synonymous variant in more than one gene, of which 6 had a 
second mutation in ZFPM2 as detailed above. Additionally, AVSD_15 had variants in 
CHD7, NIPBL and CEP152 and AVSD_72 had variants in CEP152 and NIPBL. 
Interestingly, AVSD_15 and AVSD_72 shared the same NIPBL variant (N393K), which was 
seen only in one individual in the EVS.
Discussion
We conducted a comprehensive gene analysis using next-generation sequencing in a cohort 
of unrelated AVSD probands to identify genomic variants associated with AVSD. The 
strength of our approach included a comprehensive gene selection methodology identifying 
genes with biological associations to AVSD, the majority of which have not been 
systematically examined in a large cohort of patients with AVSD. There are three important 
findings from our study.
First, genes with known biological associations to AVSD were enriched for rare and rare/
damaging non-synonymous variants compared to healthy controls. Mutation burden analysis 
at the gene level suggested an association between six genes (NIPBL, CHD7, CEP152, 
BMPR1a, ZFPM2 and MDM4) and AVSD of which the association with MDM4 remained 
significant after multiple testing. We used stringent methods to ensure that the results 
remained true when analysis was adjusted for gene-by-gene and nucleotide-by-nucleotide 
coverage between cases and controls.
Second, we demonstrated enrichment of variants in 112 genes not only in AVSD cases 
compared to EVS controls, but also in comparison to a non-AVSD cohort of TOF probands. 
This enrichment suggests that at least some of the associations were specific to AVSD and 
not to CHD in general and that there may be gene-specific cardiac phenotypes related to 
unique genetic contributions to cardiac morphogenesis.22,23 While a recent paper analyzed 
all CHD phenotypes together to identify de novo mutations,24 our results suggest the 
importance of studying probands with distinct cardiac phenotypes in order to improve the 
specificity of the observed associations and improve the predictive ability for clinical 
applications like prenatal and reproductive counselling in the future.
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Finally, “syndromic” genes were enriched for mutations despite the absence of classic 
syndromic features. These mutations were seen in patients with either isolated cardiac 
disease or subtle manifestations that did not meet diagnostic criteria for a clinical syndrome. 
In particular, three of the top-ranked associated genes were “syndromic” genes i.e. NIPBL, 
CHD7 and CEP152 suggesting that a search for mutations should include “syndromic” 
genes regardless of clinical phenotype.
An important “syndromic” gene was NIPBL, a causal gene for autosomal dominant CDL 
(OMIM 122470), a developmental disorder. Approximately 50% CDL patients have NIPBL 
variants, typically with milder phenotypes in those with missense mutations.25,26 Thirty 
percent of CDL patients have CHD, including septal defects, semilunar valve anomalies or 
AVSD.1,27 To our knowledge, isolated CHD has not previously been reported with NIPBL 
mutations.28 In our cohort, NIPBL was enriched for rare and rare-damaging variants. Yet, 
none of the probands had features of CDL syndrome (Table 4), although we cannot rule out 
subtle manifestations, as we were unable to re-contact all the probands for dysmorphology 
assessment. These findings suggest a contributory role for NIPBL not only in CHD 
associated with CDL syndrome, but also in cases with isolated AVSD.
Another “syndromic” gene enriched for variants was CHD7, the only gene known to cause 
CHARGE syndrome (OMIM 214800), a rare autosomal dominant condition with a 
prevalence of up to 1:8500.29 This was not unique to AVSD but was also seen in the TOF 
cohort, a lesion type known to be associated with CHARGE syndrome. Approximately 75% 
of individuals with CHARGE syndrome have CHD.29 Mutations in CHD7 are identified in 
over 90% of patients with the CHARGE phenotype and incomplete penetrance has not 
previously been reported.30 CHD7 was also recently reported as part of the H3K4me gene 
mutations associated with CHD.24 In our study, none of the 9 individuals with CHD7 
mutations had features of CHARGE syndrome.
CEP152, another syndromic gene, is involved in regulation of cellular response to DNA 
damage in Seckel syndrome.31 Seckel syndrome (OMIM 210600) is a rare autosomal 
recessive disorder characterized by severe growth retardation, microcephaly and mental 
retardation, as well as partial AVSD and other forms of CHD.33,33 CEP152 was enriched 
for rare non-synonymous heterozygous variants in AVSD probands, none of whom had 
features of Seckel syndrome. While at a variant level, a causal role for CEP152 appears less 
compelling, its role as a phenotype modifier cannot be excluded. Together, these findings 
reiterate that absence of obvious syndromic features should not preclude a search for 
mutations in “syndromic” genes.
Three patients had three exceptionally rare or novel variants in BMPR1a (Table 3 and Table 
S4) that were highly conserved and predicted damaging. One proband (AVSD_17) had 
unbalanced AVSD with coarctation, the same cardiac phenotype as described previously in a 
patient with a 10q22q23 deletion encompassing BMPR1a.34 Bmpr1a (Alk3) knockout mice 
show embryonic lethality between E10.5 and E11.5 with failure of endocardial cushion 
formation, failure of AV valve and adjacent septal formation, consistent with a specific and 
critical role in the formation of the AV canal.22,23 Our findings are consistent with prior 
human and animal studies that implicate BMPR1a in the development of isolated AVSD.
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ZFPM2 is a zinc-finger nuclear protein expressed in the developing heart and known to alter 
GATA4 transcriptional activity.35,36 Knock-out mouse models demonstrate cardiac defects 
including AVSD,36,37 DORV, TOF and coronary artery anomalies. ZFPM2 variants have 
also been reported in patients with conotruncal defects, but not with AVSD.38,39 The 
enrichment of variants in ZFPM2 in 9 probands in our primary AVSD cohort and 8 probands 
in the replication cohort is a new finding. Nonetheless, it is unclear if ZFPM2 variants play a 
causal or a modifier role in AVSD since the variants frequently co-segregated with variants 
in other candidate genes (Table S4), and although rare, were seen in multiple EVS cases. 
Also, the E30G variant was not specific to AVSD and has not been associated with 
functional effects on GATA4-mediated transcription and is therefore likely to be a benign 
polymorphism. 40 This is in contrast to the majority (4 of 5) of the variants identified in the 
non-AVSD TOF cohort, which were novel (Table S4).
Six AVSD probands had variants in MDM4, a p53 inhibitor, with MDM4 showing the 
strongest association with AVSD compared to the other five genes. MDM4 is involved in 
regulating endocardial EMT and subsequent proliferation of mesenchyme in the endocardial 
cushions. A mouse model heterozygous for Mdm2 and Mdm4 had impaired atrioventricular 
valvuloseptal development with significantly reduced mesenchymal cell density at the 
endocardial cushions.41 Two rare/damaging and conserved variants were identified, one of 
which was a recurring variant (K324Q) seen in five probands. The variant frequency was 
higher than controls suggesting that this variant may be potentially disease causing in AVSD 
cases.
There were some limitations to our study. Functional validation of individual variants was 
beyond the scope of this study; however all variants were in genes with known association 
with CHD. We did not assess for structural variation, frame-shift variants, or non-coding 
regulatory variants. A paucity of parental samples limited our ability to ascertain 
transmission of the variants or perform segregation analysis. Additionally, local control data 
was limited; our control population was derived from public datasets therefore we corrected 
for two limitations, coverage and population stratification.
In summary, a biology-guided approach allowed us to identify enrichment of variants in 
genes that play a central role in cardiac development in general and in AV canal 
development in particular. There is compelling data to support a contributory role for 
NIPBL, CHD7, BMPR1a, and MDM4 gene variants whereas the role of ZFPM2 variants 
and of CEP152 requires further investigation. The enrichment of variants in “syndromic” 
genes highlights the importance of not excluding these genes when investigating patients 
with non-syndromic phenotypes. Targeted search for variation in lesion-specific genes 
within next-generation sequencing data has the potential to reduce time and cost for 
bioinformatics analysis and increase the specificity and predictive accuracy of the observed 
associations.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Mutation burden analysis across 112 genes with biological relevance to AVSD.
All rare, non-synonymous variants in the gene were collapsed for each individual to allow a 
patient level analysis. Odds ratio (OR) for the number of individuals with rare non-
synonymous (blue), rare/damaging non-synonymous (red) and synonymous (green) variants 
across 112 genes in the AVSD cohort compared to EVS controls and non-AVSD CHD 
cohort with p values are shown. The AVSD cohort showed enrichment of rare non-
synonymous variants (OR 1.5, p = 4.7 x 10-11) and rare damaging non-synonymous variants 
(OR 1.3, p = 0.01) compared to EVS cohort. The AVSD cohort showed a similar enrichment 
of rare non-synonymous variants (OR 2.3, p = 2.2 x 10-14) and rare damaging non-
synonymous variants (OR 2.1, p = 2.1x10-6) compared to the non-AVSD CHD cohort. There 
was no difference between the cohorts in rare synonymous variants (AVSD vs. EVS, OR 1.0, 
p = 0.9; and AVSD vs. non-AVSD CHD, OR = 1.2 p = 0.2).
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Table 1
Primary Cohort Characteristics (n = 81 unrelated probands)
Male (n) (%) 43 (53.1%)
Mean Age at Screening (years) 14.3 ± 13
ATRIOVENTRICULAR SEPTAL DEFECT TYPE n %
Partial 34 42.0
Complete 23 28.4
Unbalanced 11 13.6
Intermediate 10 12.3
Unknown 3 3.7
OTHER ASSOCIATED CARDIAC LESIONS n %
None 49 60.5
Left Sided Lesion 18 22.2
Arterial or Venous Anomaly 6 7.4
Right Sided Lesion 4 4.9
Conotruncal 3 3.7
Unknown 1 1.2
EXTRACARDIAC ANOMALIES 18 22.2
FAMILY HISTORY OF CONGENITAL HEART DISEASE 10 12.3
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Table 3
Rare Non-Synonymous Variants in Prioritized AVSD Genes
Gene Genomic Position Base Change Amino Acid Change Rare or Novel* Predicted Damaging?* Conserved?* Proband ID
NIPBL 5:36958288 A>G N105D Rare Yes Yes AVSD_88
NIPBL 5:36962301 G>A A179T Rare No Yes AVSD_65
NIPBL 5:36976188 T>G N393K Novel No Yes AVSD_15
AVSD_72
NIPBL 5:37006555 A>G M1318V Novel Yes Yes AVSD_33
NIPBL 5:37058993 T>A S2471T Novel Yes Yes AVSD_25
CHD7 8:61654268 A>G T93A Novel No Yes AVSD_15
CHD7 8:61655009 A>G M340V Rare No Yes AVSD_13
AVSD_50
AVSD_66
AVSD_71
CHD7 8:61748826 T>C Y1325H Rare Yes Yes AVSD_79
CHD7 8:61765598 C>T A2105V Novel Yes Yes AVSD_26
CHD7 8:61768745+ C>G S2383C Novel Yes Yes AVSD_49
CHD7 8:61769418 A>C M2527L Rare No Yes AVSD_73
CEP152 15:49030841 T>C T1524A Rare No No AVSD_19
CEP152 15:49048132 G>C L1105V Rare No No AVSD_20
CEP152 15:49048567 A>G W960R Rare Yes Yes AVSD_63
AVSD_64
AVSD_72
CEP152 15:49064725 G>T L581I Novel Yes No AVSD_41
CEP152 15:49076311 T>C I394V Rare No No AVSD_15
CEP152 15:49089864 A>C S85R Rare No No AVSD_38
BMPR1a 10:88681396 A>T D429V Novel Yes Yes AVSD_17
BMPR1a 10:88683223 G>A R478H Rare Yes Yes AVSD_57
BMPR1a 10:88683231 C>T P481S Novel Yes Yes AVSD_2
ZFPM2 8:106431420 A>G E30G Rare Yes Yes AVSD_53
AVSD_74
ZFPM2 8:106456600 G>A D98N Rare Yes Yes AVSD_25
AVSD_10
AVSD_24
ZFPM2 8:106813787 C>T P361S Rare Yes Yes AVSD_53
ZFPM2 8:106813942 G>A M544I Rare No Yes AVSD_38
AVSD_46
ZFPM2 8:106814597 G>A V631I Rare Yes Yes AVSD_74
AVSD_50
ZFPM2 8:106815359 G>A G885S Rare No Yes AVSD_45
MDM4 1:204518457 A>C K324Q Rare Yes Yes AVSD_10
AVSD_39
AVSD_80
AVSD_85
AVSD_87
MDM4 1:204518499 C>G P338A Rare Yes Yes AVSD_29
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* Genomic position for human genome assembly 37/build 105. ** Refer to the Supplementary Table 4 for additional detail + With the exception of 
this variant, all variants in Table 3 were covered to a depth of ≥ 30 in the AVSD and EVS cohorts (nucleotide-by-nucleotide coverage assessment)
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Table 4
Clinical characteristics of AVSD Probands with Rare Non-Synonymous Variants in 
Prioritized AVSD Genes
Proband ID Sex AVSD Type Other Cardiac Lesions Extracardiac anomaly Gene Variant Validated? Transmitted?
AVSD_15* M Partial Double outlet LAVV None NIPBL 5:26976188 T>G o Paternal
AVSD_72* M Complete BAV (partial fusion) migraines, extra help in 
reading/math
NIPBL 5:26976188 T>G Yes Unknown
AVSD_88 F Partial None None NIPBL 5:36958288 A>G o Unknown
AVSD_65 F Partial None None NIPBL 5:36962301 G>A Yes Unknown
AVSD_33 M Unbalanced DORV, PS None NIPBL 5:37006555 A>G Yes Unknown
AVSD_25* M Intermediate None None NIPBL 5:37058993 T>A Yes Unknown
AVSD_15* M Partial Double outlet LAVV None CHD7 8:61654268 A>G o Maternal
AVSD_13 F Complete CoA, hypoplastic arch, 
PDA
LD CHD7 8:61655009 A>G Yes Unknown
AVSD_50*# M Complete None None CHD7 8:61655009 A>G Yes Maternal+
AVSD_66# F Partial None None CHD7 8:61655009 A>G Yes Unknown
AVSD_71 M Partial None hernia CHD7 8:61655009 A>G Yes Unknown
AVSD_79 F Intermediate RSCA,vertebral from AA None CHD7 8:61748826 T>C Yes Paternal
AVSD_26 F Partial None None CHD7 8:61765598 C>T Yes Maternal
AVSD_49 M Intermediate None None CHD7 8:61768745 C>G Yes Not Paternal
AVSD_73 M Unbalanced HLV & AA, CoA, LPV 
stenosis
sagittal synostosis, 
hypospadias, 
cryptorchidism, DD, 
IUGF, nephrocalcinosis
CHD7 8:61769418 A>C Yes Unknown
AVSD_19 F Complete Secundum ASD LD CEP152 15:49030841 T>C Yes Paternal
AVSD_20 M Partial None None CEP152 15:49048132 G>C Yes Unknown
AVSD_63 F Intermediate Secundum ASD, 
multiple VSD
None CEP152 15:49048567 A>G o Unknown
AVSD_64 M Complete None Hirschsprung CEP152 15:49048567 A>G Yes Maternal
AVSD_72* M Complete BAV (partial fusion) migraines, extra help in 
reading/math
CEP152 15:49048567 A>G Yes Unknown
AVSD_41 M Complete None None CEP152 15:49064725 G>T Yes Unknown
AVSD_15* M Partial Double outlet LAVV None CEP152 15:49076311 T>C o Paternal
AVSD_38*# M Partial None None CEP152 15:49089864 A>C Yes Unknown
AVSD_17 F Unbalanced CoA, LSVC to CS None BMPR1a 10:88681396 G>T Yes Maternal
AVSD_57# M Complete multiple VSD, LSVC to 
CS
LD, psychiatric, 
cervical spine 
anomalies
BMPR1a 10:88683223 G>A Yes Unknown
AVSD_2 F Complete None None BMPR1a 10:88683231 C>T Yes Unknown
AVSD_53* F Complete PA/MAPCAS, LSVC to 
CS
Bilateral coloboma, 
bicornuate uterus, 
Bockdalek 
diaphragmatic hernia, 
midline spleen, 
hydrocephalus
ZFPM2 8:106431420 C>G Yes Unknown
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Proband ID Sex AVSD Type Other Cardiac Lesions Extracardiac anomaly Gene Variant Validated? Transmitted?
AVSD_74*# F Partial None None ZFPM2 8:106431420 C>G Yes Unknown
AVSD_10* M Partial PDA None ZFPM2 8:106456600 G>A Yes Unknown
AVSD_24 M Complete None None ZFPM2 8:106456600 G>A Yes Paternal
AVSD_25* M Intermediate None None ZFPM2 8:106456600 G>A Yes Unknown
AVSD_53* F Complete PA/MAPCAS, LSVC to 
CS
Bilateral coloboma, 
bicornuate uterus, 
Bockdalek 
diaphragmatic hernia, 
midline spleen, 
hydrocephalus
ZFPM2 8:106813787 C>T Yes Unknown
AVSD_38*# M Partial None None ZFPM2 8:106813942 G>A Yes Unknown
AVSD_46 M Complete None None ZFPM2 8:106813942 G>A Yes Unknown
AVSD_50*# M Complete None None ZFPM2 8:106814597 G>A Yes Paternal
AVSD_74*# F Partial None None ZFPM2 8:106814597 G>A Yes Unknown
AVSD_45 F Partial PDA Congenital rubella 
syndrome, epilepsy, 
hearing impairment, 
blindness, psychiatric 
disorder
ZFPM2 8:106815359 G>A Yes Unknown
AVSD_10* M Partial PDA None MDM4 1:204518457 A>C Yes Unknown
AVSD_39 F Complete LVOTO None MDM4 1:204518457 A>C Yes Paternal
AVSD_80 M Unknown LVOTO None MDM4 1:204518457 A>C Yes Unknown
AVSD_85 M Complete LSVC to CS, RAA None MDM4 1:204518457 A>C Yes Unknown
AVSD_87 F Partial PDA None MDM4 1:204518457 A>C Yes Unknown
AVSD_29 F Partial PDA None MDM4 1:204518499 C>G Yes Paternal
Genomic position for human genome assembly 37/build 105. All variants are heterozygous. * probands with > 1 variant, o sample/validation not 
available, +Inherited from mother also affected with AVSD, # of CHD family history
Abbreviations: M – male, F – female; AA - aortic arch, ASD - atrial septal defect, BAV - bicuspid aortic valve, CoA - coarctation of the aorta, 
DORV - double outlet right ventricle, HLV - hypoplastic left center ventricle, LAVV - left center atrioventricular valve, LPV - left center 
pulmonary vein, LSVC to CS - left center superior vena cava to the coronary sinus, LVOTO - left center ventricular outflow tract obstruction, PA/
MAPCAS - pulmonary atresia with major aortopulmonary collaterals, PDA - patent ductus arteriosus, RAA - right aortic arch, RSCA - right 
subclavian artery, VSD - ventricular septal defect
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